Icotinib In The Treatment Of Advanced Non-small Cell Lung Cancer In Chinese Population:A Meta-analysis

Objective: This study is Conducted to evaluate the efficacy and safety of icotinib verus gefitinib or erlotinib in the treatment of Chinese population with advanced non-small cell lung cancer(NSCLC).Compared the effective rate,disease control rate and adverse reactions such as rash,diarrhea,liver function injury,and evaluated the results by metaanalysis.provide circular evidence for clinical rational use of targeted drugs in Chinese population with NSCLC.Methods: Such data is based on CNKI,wangfang data,CBM,VIP,Pub Med,Cochrane Library and so on.comprehensively collecting the randomized controlled trials about icotinib verus gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer in Chinese population,The intervention measures is that the experimental group uses icotinib treatment and the control group uses gefitinib or erlotinib and the related studies mentioned in all included documents are researched futher.Retrieval time is from the time of database builded to October 2017.The retried documents are screened according to inclusion criteria and exclusion criteria,whose result is analyzed by using Revman5.3 software.Results:This paper includes 13 studies,which involve 1169 Chinese patients with advanced NSCLC.There are 591 patients in the experimental group and 578 patients in the control group.The results of Meta analysis shows:1.there was statistical significance of the effective rate between the two groups(P=0.04),but the lower limit of 95%CI [1.01,1.40] is close to 1,the result is of little clinical significance.2.there was no statistical significant difference of the disease control rate between the two groups(RR=1.06,95% CI [0.98,1.16],P =0.13).3.there was statistical significant difference of the incidence of rash between the two groups(RR=0.76,95% CI [0.64,0.90],P =0.002).4.there was statistical significant difference of the incidence of diarrhea between the two groups(RR=0.73,95% CI [0.57,0.93],P=0.01).5.there was statistical significant difference of the incidence of liver function injury between the two groups(RR=0.64,95% CI [0.43,0.96],P=0.03).Conclusion: Icotinib and gefitinib or erlotinib in the treatment of Chinese population with advanced NSCLC,we find that there was no significant difference in efficacy between the two groups,but the occurrence rate of rash,diarrhea,liver function injury in icotinib group is lower than gefitinib or erlotinib group.Thus,icotinib is better than gefitinib or erlotinib in the safety and patients tolerance,and it can be used to treat Chinese population with advanced NSCLC as the targeted drug.